Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Conclusions The recommended phase 2 dosage of LY3007113 was 30  mg Q12H. Three patients continued treatment after the first radiographic assessment, and the BED was not achieved. Further clinical development of this compound is not planned as toxicity precluded achieving a biologically effective dose.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research